Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
20 oct. 2022 08h00 HE
|
Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
14 oct. 2022 08h30 HE
|
Novan, Inc.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for...
With 8.7% CAGR, Psoriasis Treatment Market Size worth USD 47.24 billion by [2022-2029]
07 oct. 2022 07h31 HE
|
Fortune Business Insights
Pune, India, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The psoriasis treatment market size was USD 24.33 billion in 2021. The market is projected to grow from USD 26.37 billion in 2022 to USD 47.24 billion...
$11+ Billion Dermatology Devices Market Size to Grow at 11.2% CAGR, Globally, by 2028 - Growing Prevalence of Skin Cancers and Skin Disorders
30 sept. 2022 08h00 HE
|
The Insight Partners
New York, Sept. 30, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology Devices Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast...
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
15 sept. 2022 08h00 HE
|
Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
07 sept. 2022 01h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients
22 août 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford...
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
29 juil. 2022 16h05 HE
|
Arcutis Biotherapeutics, Inc.
First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque...
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
18 juil. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Insights on the Dermatology Diagnostic Devices Global Market to 2027 - by Product Type, End-use and Region
27 mai 2022 08h13 HE
|
Research and Markets
Dublin, May 27, 2022 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...